{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:17:25Z","timestamp":1760300245351,"version":"3.37.3"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T00:00:00Z","timestamp":1563321600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T00:00:00Z","timestamp":1563321600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"National Key R&D Program of China","award":["2016YFC0902603"],"award-info":[{"award-number":["2016YFC0902603"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81572523"],"award-info":[{"award-number":["81572523"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s12094-019-02181-0","type":"journal-article","created":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T06:02:50Z","timestamp":1563343370000},"page":"725-733","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Prognostic factors for the survival of patients with papillary renal cell carcinoma after surgical management"],"prefix":"10.1007","volume":"22","author":[{"given":"W.","family":"Ren","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6346-6674","authenticated-orcid":false,"given":"X.","family":"Zu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,17]]},"reference":[{"key":"2181_CR1","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1002\/cam4.1048","volume":"6","author":"J Connor Wells","year":"2017","unstructured":"Connor Wells J, Donskov F, Fraccon AP, et al. Characterizing the outcomes of metastatic papillary renal cell carcinoma. Cancer Med. 2017;6:902\u20139. \nhttps:\/\/doi.org\/10.1002\/cam4.1048\n\n.","journal-title":"Cancer Med."},{"key":"2181_CR2","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1590\/S1677-5538.IBJU.2017.0519","volume":"44","author":"W Ren","year":"2018","unstructured":"Ren W, Xue B, Qu J, Liu L, Li C, Zu X. Localized chromophobe renal cell carcinoma: preoperative imaging judgment and laparoscopic simple enucleation for treatment. Int Braz J Urol. 2018;44:922\u201332. \nhttps:\/\/doi.org\/10.1590\/S1677-5538.IBJU.2017.0519\n\n.","journal-title":"Int Braz J Urol."},{"key":"2181_CR3","first-page":"537","volume":"10","author":"B Delahunt","year":"1997","unstructured":"Delahunt B, Eble JN. Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol. 1997;10:537\u201344.","journal-title":"Mod Pathol"},{"key":"2181_CR4","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1056\/NEJMoa1505917","volume":"374","author":"The Cancer Genome Atlas Research Network","year":"2016","unstructured":"The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of papillary renal-cell carcinoma. N Engl J Med. 2016;374:135\u201345. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1505917\n\n.","journal-title":"N Engl J Med."},{"key":"2181_CR5","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/j.humpath.2014.02.004","volume":"45","author":"JI Warrick","year":"2014","unstructured":"Warrick JI, Tsodikov A, Kunju LP, et al. Papillary renal cell carcinoma revisited: a comprehensive histomorphologic study with outcome correlations. Hum Pathol. 2014;45:1139\u201346. \nhttps:\/\/doi.org\/10.1016\/j.humpath.2014.02.004\n\n.","journal-title":"Hum Pathol"},{"key":"2181_CR6","doi-asserted-by":"publisher","first-page":"68e73","DOI":"10.1038\/ng0597-68","volume":"16","author":"L Schmidt","year":"1997","unstructured":"Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet. 1997;16:68e73.","journal-title":"Nat Genet"},{"key":"2181_CR7","first-page":"2163e72","volume":"170","author":"WM Linehan","year":"2003","unstructured":"Linehan WM, Walther MM, Zbar B. The genetic basis of cancer of the kidney. J Urol. 2003;170:2163e72.","journal-title":"J Urol"},{"key":"2181_CR8","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1016\/j.ejca.2012.05.002","volume":"48","author":"S Steffens","year":"2012","unstructured":"Steffens S, Janssen M, Roos FC, et al. Incidence and long-term prognosis of papillary compared to clear cell renal cell carcinoma\u2013a multicentre study. Eur J Cancer. 2012;48:2347\u201352. \nhttps:\/\/doi.org\/10.1016\/j.ejca.2012.05.002\n\n.","journal-title":"Eur J Cancer"},{"key":"2181_CR9","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00345-015-1692-3","volume":"34","author":"RA Ledezma","year":"2016","unstructured":"Ledezma RA, Negron E, Paner GP, et al. Clinically localized type 1 and 2 papillary renal cell carcinomas have similar survival outcomes following surgery. World J Urol. 2016;34:687\u201393. \nhttps:\/\/doi.org\/10.1007\/s00345-015-1692-3\n\n.","journal-title":"World J Urol"},{"issue":"23","key":"2181_CR10","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.celrep.2018.03.075","volume":"3","author":"CJ Ricketts","year":"2018","unstructured":"Ricketts CJ, De Cubas AA, Fan H, et al. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Rep. 2018;3(23):313\u201326. \nhttps:\/\/doi.org\/10.1016\/j.celrep.2018.03.075\n\n.","journal-title":"Cell Rep."},{"key":"2181_CR11","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.eururo.2017.06.040","volume":"72","author":"RH Giles","year":"2017","unstructured":"Giles RH, Choueiri TK, Heng DY, et al. Recommendations for the management of rare kidney cancers. Eur Urol. 2017;72:974\u201383. \nhttps:\/\/doi.org\/10.1016\/j.eururo.2017.06.040\n\n.","journal-title":"Eur Urol."},{"key":"2181_CR12","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.urology.2006.09.052","volume":"69","author":"G Pignot","year":"2007","unstructured":"Pignot G, Elie C, Conquy S, et al. Survival analysis of 130 patients with papillary renal cell carcinoma: prognostic utility of type 1 and type 2 subclassification. Urology. 2007;69:230\u20135.","journal-title":"Urology"},{"key":"2181_CR13","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1097\/00000478-198210000-00007","volume":"6","author":"SA Fuhrman","year":"1982","unstructured":"Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6:655\u201363.","journal-title":"Am J Surg Pathol"},{"key":"2181_CR14","volume-title":"The TNM classification of malignant tumors","year":"2009","unstructured":"Sobin LH, Gospodarowicz MK, Wittekind C, editors. The TNM classification of malignant tumors. 7th ed. Wiley-Blackwell: International Union Against Cancer; 2009.","edition":"7"},{"key":"2181_CR15","doi-asserted-by":"publisher","first-page":"193e205","DOI":"10.1016\/j.ctrv.2007.12.001","volume":"34","author":"K Gupta","year":"2008","unstructured":"Gupta K, Miller JD, Li JZ, et al. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev. 2008;34:193e205.","journal-title":"Cancer Treat Rev"},{"key":"2181_CR16","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1177\/1066896909354337","volume":"19","author":"Q Rao","year":"2011","unstructured":"Rao Q, Chen JY, Wang JD, et al. Renal cell carcinoma in children and young adults: clinicopathological, immuno-histochemical, and VHL gene analysis of 46 cases with follow-up. Int J Surg Pathol. 2011;19:170\u20139.","journal-title":"Int J Surg Pathol"},{"key":"2181_CR17","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.critrevonc.2015.05.008","volume":"96","author":"G Courthod","year":"2015","unstructured":"Courthod G, Tucci M, Di Maio M, et al. Papillary renal cell carcinoma: a review of the current therapeutic landscape. Crit Rev Oncol Hematol. 2015;96:100\u201312.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2181_CR18","first-page":"487","volume":"18","author":"N Kuroda","year":"2003","unstructured":"Kuroda N, Toi M, Hiroi M, et al. Review of papillary renal cell carcinoma with focus on clinical and pathobiological aspects. Histol Histopathol. 2003;18:487\u201394.","journal-title":"Histol Histopathol"},{"key":"2181_CR19","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1097\/01.ju.0000081122.57148.ec","volume":"170","author":"A Mejean","year":"2003","unstructured":"Mejean A, Hopirtean V, Bazin JP, et al. Prognostic factors for the survival of patients with papillary renal cell carcinoma: meaning of histological typing and multifocality. J Urol. 2003;170:764\u20137.","journal-title":"J Urol"},{"key":"2181_CR20","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.afju.2015.08.003","volume":"22","author":"MM Gargouri","year":"2016","unstructured":"Gargouri MM, Ayari Y, Ben CM, et al. Clinical and pathological features of papillary renal cell carcinoma and prognostic value of its type-1 and type-2 subtypes. Afr J Urol. 2016;22:149\u201352.","journal-title":"Afr J Urol"},{"key":"2181_CR21","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1002\/cncr.24841","volume":"116","author":"AP Noon","year":"2010","unstructured":"Noon AP, Vlatkovi\u0107 N, Pola\u0144ski R, et al. p53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets. Cancer. 2010;116:780\u201390.","journal-title":"Cancer"},{"key":"2181_CR22","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.juro.2009.12.035","volume":"183","author":"BC Leibovich","year":"2010","unstructured":"Leibovich BC, Lohse CM, Crispen PL, et al. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol. 2010;183:1309\u201315. \nhttps:\/\/doi.org\/10.1016\/j.juro.2009.12.035\n\n.","journal-title":"J Urol"},{"issue":"23","key":"2181_CR23","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1200\/JCO.2005.07.055","volume":"20","author":"JJ Patard","year":"2005","unstructured":"Patard JJ, Leray E, Rioux-Leclercq N, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol. 2005;20(23):2763\u201371.","journal-title":"J Clin Oncol"},{"key":"2181_CR24","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1053\/hupa.2001.24984","volume":"32","author":"B Delahunt","year":"2001","unstructured":"Delahunt B, Eble JN, McCredie MR, et al. Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases. Hum Pathol. 2001;32:590\u20135.","journal-title":"Hum Pathol"},{"key":"2181_CR25","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1038\/bjc.2013.119","volume":"108","author":"T Wahlgren","year":"2013","unstructured":"Wahlgren T, Harmenberg U, Sandstr\u00f6m P, et al. Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000\u20132008). Br J Cancer. 2013;108:1541\u20139. \nhttps:\/\/doi.org\/10.1038\/bjc.2013.119\n\n.","journal-title":"Br J Cancer"},{"key":"2181_CR26","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/cam4.574","volume":"5","author":"P Li","year":"2016","unstructured":"Li P, Wong YN, Armstrong K, et al. Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras. Cancer Med. 2016;5:169\u201381. \nhttps:\/\/doi.org\/10.1002\/cam4.574\n\n.","journal-title":"Cancer Med"},{"key":"2181_CR27","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ejca.2016.08.004","volume":"69","author":"B Escudier","year":"2016","unstructured":"Escudier B, Molinie V, Bracarda S, et al. Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis. Eur J Cancer. 2016;69:226\u201335. \nhttps:\/\/doi.org\/10.1016\/j.ejca.2016.08.004\n\n.","journal-title":"Eur J Cancer"},{"key":"2181_CR28","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1093\/annonc\/mdv149","volume":"26","author":"A Ravaud","year":"2015","unstructured":"Ravaud A, Oudard S, De Fromont M, et al. First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG). Ann Oncol. 2015;26:1123\u20138. \nhttps:\/\/doi.org\/10.1093\/annonc\/mdv149\n\n.","journal-title":"Ann Oncol"},{"key":"2181_CR29","doi-asserted-by":"publisher","first-page":"E673","DOI":"10.1111\/j.1464-410X.2012.11498.x","volume":"110","author":"KH Kim","year":"2012","unstructured":"Kim KH, You D, Jeong IG, et al. Type II papillary histology predicts poor outcome in patients with renal cell carcinoma and vena cava thrombus. BJU Int. 2012;110:E673\u2013E678678. \nhttps:\/\/doi.org\/10.1111\/j.1464-410X.2012.11498.x\n\n.","journal-title":"BJU Int"},{"key":"2181_CR30","doi-asserted-by":"crossref","unstructured":"Ha YS, Chung JW, Choi SH, et al. Korean Renal Cell Carcinoma Study Group. Clinical Significance of Subclassification of Papillary Renal Cell Carcinoma: Comparison of Clinicopathologic Parameters and Oncologic Outcomes Between Papillary Histologic Subtypes 1 and 2 Using the Korean Renal Cell Carcinoma Database. Clin Genitourin Cancer. 2017;15:e181\u20136.","DOI":"10.1016\/j.clgc.2016.07.020"},{"key":"2181_CR31","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s00345-015-1634-0","volume":"34","author":"P Bigot","year":"2016","unstructured":"Bigot P, Bernhard JC, Gill IS, et al. The subclassification of papillary renal cell carcinoma does not affect oncological outcomes after nephron sparing surgery. World J Urol. 2016;34:347\u201352.","journal-title":"World J Urol"},{"key":"2181_CR32","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1111\/j.1464-410X.2011.10517.x","volume":"109","author":"A Zucchi","year":"2012","unstructured":"Zucchi A, Novara G, Costantini E, et al. Prognostic factors in a large multi-institutional series of papillary renal cell carcinoma. BJU Int. 2012;109:1140\u20136.","journal-title":"BJU Int"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-019-02181-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12094-019-02181-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-019-02181-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T23:40:36Z","timestamp":1594856436000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12094-019-02181-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,17]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["2181"],"URL":"https:\/\/doi.org\/10.1007\/s12094-019-02181-0","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"type":"print","value":"1699-048X"},{"type":"electronic","value":"1699-3055"}],"subject":[],"published":{"date-parts":[[2019,7,17]]},"assertion":[{"value":"13 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}